1. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients.
- Author
-
Escolà, H., Figueras‐Nart, I., Bonfill‐Orti, M., Coll Puigserver, N., Martin‐Santiago, A., Rodríguez Serna, M., Sánchez Hernández, M. C., Sanz‐Cabanillas, J. L., Taberner, R., Zaragoza‐Ninet, V., Pujol, R. M., and Curto‐Barredo, L.
- Subjects
ATOPIC dermatitis ,DUPILUMAB ,PREGNANCY ,ANKYLOGLOSSIA ,BREASTFEEDING ,PATIENTS' attitudes - Abstract
Patients' characteristics, treatments received before dupilumab, reasons that led to initiate this treatment as well as the cause of treatment discontinuation are mentioned in Table 1. Duration of 9 month during pregnancy and 1 month during breastfeeding
- Patient 12 34 25 Caucasian Asthma Topical and systemic corticosteroids, cyclosporine Unknown Before pregnancy Shared decision-making was adopted after a risk-benefit assessment, discussing the course of AD, safety data, potential therapeutic options and previous response to systemic treatments Left the treatment. [Extracted from the article] - Published
- 2023
- Full Text
- View/download PDF
2. Transcriptome analysis of severely active chronic spontaneous urticaria shows an overall immunological skin involvement.
- Author
-
Giménez‐Arnau, A., Curto‐Barredo, L., Nonell, L., Puigdecanet, E., Yelamos, J., Gimeno, R., Rüberg, S., Santamaria‐Babi, L., and Pujol, R.M.
- Subjects
- *
TREATMENT effectiveness , *URTICARIA , *PHENOTYPES , *COMORBIDITY , *GENE expression , *TREATMENT of urticaria , *PATIENTS - Abstract
Background The knowledge about chronic spontaneous urticaria (CSU) phenotypes is based on its clinical characteristics, associated comorbidities, course of the disease, and its response to the available effective drugs. Genotype expression and its further correlation with CSU phenotypes are still unknown. We describe the cutaneous transcriptome of patients suffering a severely active CSU refractory to antihistamine treatment. Methods Through the bioinformatic analysis of the whole Human Genome with Oligo Microarrays and quantitative real-time polymerase chain reaction (qPCR), relevant genes expressed in nonlesional (NLS-CSU) and lesional skin (LS-CSU) and peripheral blood were identified in 20 patients suffering from severely active CSU and 10 healthy controls (HCs). Results From 39 genes differentially expressed in NLS-CSU when compared with HCs, 31 (79.48%) were confirmed by qPCR corresponding to genes involved in epidermal homeostasis and dermal repair. From the analysis comparing LS-CSU with NLS-CSU, a selection of 142 genes was studied with qPCR, and 103 (72.53%) were confirmed. Differentially expressed genes in the phenomenon of wheal development are involved in a variety of biological functions as, epidermal differentiation, intracellular signal function, transcriptional factors cell cycle differentiation, inflammation, or coagulation. Differentially expressed genes that uniformly increase or decrease along the skin worsening until the wheal appearance is shown. Conclusion The skin of CSU patients with a severely active disease shows an overall immunological skin involvement showing a peculiar gene profile. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases.
- Author
-
González ‐ Medina, M., Curto ‐ Barredo, L., Labrador ‐ Horrillo, M., and Giménez ‐ Arnau, A.
- Subjects
- *
CHRONIC diseases , *ADRENOCORTICAL hormones , *HORMONE therapy , *PREGNANCY complications , *DISEASE exacerbation - Abstract
The article presents case studies involving chronic spontaneous urticaria (CSU). It mentions that first patient, which developed severe exacerbations, received treatment with short courses of oral corticosteroid. It mentions that second patient developed a sudden worsening during pregnancy despite treatment with omalizumab. It reveals that two cases were reported to the official pharmacosurveillance system.
- Published
- 2017
- Full Text
- View/download PDF
4. Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
- Author
-
Melé-Ninot G, Curto-Barredo L, Bonfill-Ortí M, Expósito-Serrano V, Munera-Campos M, Figueras Nart I, Riquelme-Mc Loughlin C, Gómez-Armayones S, Spertino J, and Serra-Baldrich E
- Subjects
- Adult, Male, Humans, Female, Young Adult, Middle Aged, Retrospective Studies, Double-Blind Method, Severity of Illness Index, Treatment Outcome, Immunoglobulin A, Dermatitis, Atopic drug therapy, Dermatitis, Atopic diagnosis, Eczema, Antibodies, Monoclonal, Humanized
- Abstract
Background: Dupilumab has shown to be an effective and safe treatment for patients with moderate-to-severe atopic dermatitis (AD)., Objective: To evaluate the predictive factors of response (PRF) in patients with moderate-to-severe AD treated with dupilumab., Methods: Observational, retrospective and multicentre study conducted on adult patients diagnosed with moderate-to-severe AD treated with dupilumab, with a post-treatment follow-up of at least 16 weeks. The primary endpoints were EASI-75 and the IGA scale at week 52., Results: A total of 198 patients were included in the analysis. Mean age was 38 ± 15.1 years and 116 (58.6%) were men. The most prevalent AD-predominant phenotypes were flexural eczema (45.3%), head-and-neck eczema (18.2%) and erythroderma (17.7%). At week 52, 140 (86.4%) patients achieved EASI-75 and 119 (93.0%) achieved an improvement in ≥2 points from baseline in IGA score. Women were 3.6 times more likely to achieve EASI-75 response than men (Odds ratio: 3.58; p = 0.020). While increased body mass index significantly reduced the probability of obtaining an improvement of ≥2 points in the IGA scale at week 52 (odds ratio: 0.88; p = 0.049)., Conclusions: Dupilumab was an effective treatment in patients with moderate-to-severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI-75 and an improvement of ≥2 points in the IGA scale, respectively, at week 52., (© 2023 Australasian College of Dermatologists.)
- Published
- 2024
- Full Text
- View/download PDF
5. SEB-induced IL-13 production in CLA + memory T cells defines Th2 high and Th2 low responders in atopic dermatitis.
- Author
-
Sans-De San Nicolàs L, Figueras-Nart I, Bonfill-Ortí M, De Jesús-Gil C, García-Jiménez I, Guilabert A, Curto-Barredo L, Bertolín-Colilla M, Ferran M, Serra-Baldrich E, Zalewska-Janowska A, Wang YH, Howell MD, Pujol RM, and Santamaria-Babí LF
- Subjects
- Humans, Interleukin-13, Memory T Cells, Th2 Cells, Enterotoxins pharmacology, Th1 Cells, Skin, Dermatitis, Atopic
- Published
- 2022
- Full Text
- View/download PDF
6. Pemphigus-like hypereosinophilic syndrome with FIP1L1-PDGFRA fusion gene: A challenging and uncommon clinical presentation.
- Author
-
Curto-Barredo L, Segura S, Ishii N, Hashimoto T, Mascaró JM Jr, Espinet B, Besses C, and Pujol RM
- Subjects
- Diagnosis, Differential, Humans, Hypereosinophilic Syndrome drug therapy, Hypereosinophilic Syndrome genetics, Hypereosinophilic Syndrome immunology, Imatinib Mesylate pharmacology, In Situ Hybridization, Fluorescence, Male, Middle Aged, Mouth Mucosa immunology, Mouth Mucosa pathology, Oncogene Proteins, Fusion antagonists & inhibitors, Receptor, Platelet-Derived Growth Factor alpha antagonists & inhibitors, Severity of Illness Index, Stomatitis drug therapy, Stomatitis genetics, Stomatitis immunology, Treatment Outcome, mRNA Cleavage and Polyadenylation Factors antagonists & inhibitors, Hypereosinophilic Syndrome diagnosis, Imatinib Mesylate therapeutic use, Oncogene Proteins, Fusion genetics, Pemphigus diagnosis, Receptor, Platelet-Derived Growth Factor alpha genetics, Stomatitis diagnosis, mRNA Cleavage and Polyadenylation Factors genetics
- Abstract
Hypereosinophilic syndrome (HES) is often associated with cutaneous manifestations, mostly pruritic lesions, urticaria and angioedema. Mucosal lesions are rarely seen in HES but, when present, are usually the first manifestation of the disease. The clinical presentation may be heterogeneous, including erosions, aphthae or ulcers, and can be easily confused with other mucocutaneous disorders. Here, we present the case of a 64-year-old man with severe chronic erosive oral mucositis simulating pemphigus in which the finding of persistent eosinophilia and elevation of B
12 vitamin serum levels raised the suspicion of HES. The FIP1L1-PDGFRA fusion gene (4q12) was detected by fluorescence in situ hybridization and the patient was treated with imatinib mesylate with complete response of the disease., (© 2019 Japanese Dermatological Association.)- Published
- 2019
- Full Text
- View/download PDF
7. Successful treatment of hypertrophic herpes simplex genitalis in HIV-infected patient with topical imiquimod.
- Author
-
Deza G, Martin-Ezquerra G, Curto-Barredo L, Villar García J, and Pujol RM
- Subjects
- Adjuvants, Immunologic administration & dosage, Administration, Topical, Herpes Genitalis pathology, Humans, Hypertrophy, Imiquimod, Male, Middle Aged, Aminoquinolines administration & dosage, HIV Infections complications, Herpes Genitalis complications, Herpes Genitalis drug therapy
- Abstract
Hypertrophic herpes simplex genitalis is an atypical presentation of genital herpes described in the context of immunosuppression, particularly HIV-positive patients. This situation can become a diagnostic and therapeutic challenge. For this reason, alternative therapies are currently being discussed in the literature. We report a case of hypertrophic genital herpes in a HIV-positive patient who was successfully treated with topical 5% imiquimod after treatment failures with oral and i.v. antivirals., (© 2015 Japanese Dermatological Association.)
- Published
- 2015
- Full Text
- View/download PDF
8. Anagen effluvium due to thallium poisoning derived from the intake of Chinese herbal medicine and rodenticide containing thallium salts.
- Author
-
Curto-Barredo L, Segura S, Martín-Ezquerra G, Lloveras B, Gallardo F, and Pujol RM
- Subjects
- Adult, Alopecia chemically induced, Child, Drugs, Chinese Herbal adverse effects, Female, Humans, Alopecia pathology, Hair pathology, Rodenticides poisoning, Thallium poisoning
- Published
- 2015
- Full Text
- View/download PDF
9. Lenalidomide-induced paronychia.
- Author
-
Curto Barredo L, Salar A, Pujol RM, Garcia M, and Gallardo F
- Subjects
- Adult, Female, Hodgkin Disease drug therapy, Humans, Lenalidomide, Thalidomide adverse effects, Angiogenesis Inhibitors adverse effects, Paronychia chemically induced, Thalidomide analogs & derivatives
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resourcesDiscovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.